Cablivi (caplacizumab) approved in Europe for adults with aTTP
The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic…
Read More...
Read More...
